Thus, HCC patients who are heterozygous for variants rs1045642 in ABCB1, and rs2231137 and rs2231142 in ABCG2, have lower sorafenib plasma levels and better clinical evolution [21]. This evidence concerns the gene ABCB1 and hepatocellular carcinoma.